Amylin Pharma (AMLN) Posts Wider than Expected Q2 Loss; Revs Beat
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Join SI Premium – FREE
Amylin Pharma (NASDAQ: AMLN) reported Q2 loss of ($0.21), $0.03 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $158.07 million versus the consensus estimate of $157.72 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
